PRLD Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 44.38%, SMA50 44.7%, SMA200 127.94%). The stock’s 14-day RSI is 74.1 (overbought), while the ATR of 0.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.04% below its high and over 439.26% above its low. Average 10-day trading volume of 515.98 thousand shares is slightly above the 3-month average of 450.18 thousand, indicating heightened recent market interest.

Prelude Therapeutics Incorporated has 43.75 million shares outstanding. The public float is 29.18 million shares, elevated short interest at 6.78% of float. This equals 510.20 thousand shares. The short ratio is 4.1 days. Institutional investors hold 70.31% of the float. Insiders own 11.34%. ORBIMED ADVISORS LLC holds 10.12 million shares, Bonita David P has 10.12 million shares and Vaddi Krishna has 2.00 million shares.

Prelude Therapeutics Incorporated generated EPS of -$1.61 over the past year. Five-year average earnings growth is -21.61%. The latest quarter delivered EPS of -$0.26. The next quarter is forecast at -$0.03. Next year's EPS is expected at $5.43. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $3.00. The high target offers 51.98% upside. The low target suggests -8.81% downside. The mean target is $4.25. This offers 29.18% upside. Prelude Therapeutics Incorporated earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -25.97%. The prior quarter beat by -8.89%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 12, 2024.

Prelude Therapeutics Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.84. This means the shares are trading above this model’s fair value.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) closed at $3.29 USD, gaining $0.43 (15.03%) from the previous close of $2.86. The stock is currently mid-range between its 52-week high and low $0.61 and $4.22. With a market capitalization of about $181.56 million, Prelude Therapeutics Incorporated is classified as a micro-cap and shows market-like volatility (beta ~0.87). Key stats such as the average daily volume over the past year has been around 440.80 thousand shares, trading with heavier-than-usual volume. Headquartered in Wilmington, DE, Prelude Therapeutics Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Krishna Vaddi, the company employs approximately 131 people and listed since September 25, 2020. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Our AI price prediction model suggests that Prelude Therapeutics Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.52%, with price expected at $3.24 by March 11, 2026, within a range of $2.95 to $3.53 3-Month Outlook: Projected rise of 19.15%, reaching $3.92 by May 26, 2026, with a range of $3.64 to $4.14. 1-Year Outlook: Projected gain of 863.22%, with price at $31.69 by February 25, 2027, within a range of $31.59 to $39.51.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) shares are down -36.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Prelude Therapeutics Incorporated trading at a premium to the broader market with a P/E of -2.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.48, suggesting 461.7% upside. Our AI forecast model points to short-term weakness (-1.52% over two weeks), a medium-term rise (19.15% over three months), and a longer-term gain (863.22% over one year), with expected trading ranges indicating moderate volatility.

Prelude Therapeutics Incorporated trades at a P/E ratio of -2.16, slightly below the S&P 500 average, with a price-to-sales ratio of 16.63 and a price-to-book ratio of 4.12 trading at moderately above to book value. The P/FCF stands at -1.74, also above market averages.